MARKET

BEAM

BEAM

Beam Therapeutics Inc.
NASDAQ
24.27
-0.39
-1.58%
After Hours: 24.60 +0.33 +1.36% 16:23 09/25 EDT
OPEN
24.97
PREV CLOSE
24.66
HIGH
24.97
LOW
23.75
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
38.26
52 WEEK LOW
20.23
MARKET CAP
2.51B
P/E (TTM)
-29.7901
1D
5D
1M
3M
1Y
5Y
1D
Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement
Seeking Alpha · 25m ago
Squeeze Watch: 10 Stocks With Over 33% Short Interest
Benzinga · 2h ago
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing
Seeking Alpha · 1d ago
AM Markets Need to Know: F-35 parts end up in Chinese custody, Google nears Gemini 4 launch, and more
Seeking Alpha · 1d ago
Beam Therapeutics (BEAM) Stock Looks Fully Valued Despite In Vivo Gene Editing Growth
Simply Wall St · 1d ago
Gene editing stocks fall after report on Anthropic’s CRISPR-like discovery
Seeking Alpha · 2d ago
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Benzinga · 3d ago
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The Motley Fool · 3d ago
More
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Webull offers Beam Therapeutics Inc stock information, including NASDAQ: BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.